Brian Thomas, Metagenomi CEO

No in­tro­duc­tions nec­es­sary: A TCR up­start with deep-pock­et back­ers part­ners with one of the new play­ers in the hot gene edit­ing field

When Affi­ni-T ar­rived on the scene a few weeks ago, it had most of the es­sen­tial el­e­ments need­ed by any biotech up­start.

There were high-pro­file sci­en­tif­ic founders, Phil Green­berg, Tom Schmitt and Aude Cha­puis, at the Fred Hutch. A moth­er­lode of cash from am­bi­tious in­vestors like Vi­da Ven­tures and Leaps by Bay­er. And the build­ing blocks of new drugs to go af­ter onco­genic dri­vers like KRAS and p53.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.